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Renal angiomyolipomas are one of the most common renal manifestations in patients
with tuberous sclerosis complex (TSC), with potentially life-threatening complications and
a poor prognosis. Despite the considerable progress in understanding TSC-associated
renal angiomyolipomas, there are no large scale real-world data. The aim of our present
study was to describe in detail the prevalence and outcome of renal angiomyolipomas
in patients with TSC, enrolled into the TuberOus SClerosis registry to increase disease
Awareness (TOSCA) from 170 sites across 31 countries worldwide. We also sought to
evaluate the relationship of TSC-associated renal angiomyolipomas with age, gender
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and genotype. The potential risk factors for renal angiomyolipoma-related bleeding and
chronic kidney disease (CKD) were studied in patients who participated in the TOSCA
renal angiomyolipoma substudy. Of the 2,211 eligible patients, 1,062 (48%) reported a
history of renal angiomyolipomas. The median age of TSC diagnosis for the all subjects
(n = 2,211) was 1 year. The median age of diagnosis of renal angiomyolipoma in the
1,062 patients was 13 years. Renal angiomyolipomas were significantly more prevalent
in female patients (p < 0.0001). Rates of angiomyolipomas >3 cm (p= 0.0119), growing
lesions (p = 0.0439), and interventions for angiomyolipomas (p = 0.0058) were also
higher in females than males. Pre-emptive intervention for renal angiomyolipomas with
embolisation, surgery, or mammalian target of rapamycin (mTOR) inhibitor may have
abolished the gender difference in impaired renal function, hypertension, and other
complications. The rate of interventions for angiomyolipomas was less common in
children than in adults, but interventions were reported in all age groups. In the substudy
of 76 patients the complication rate was too low to be useful in predicting risk for
more severe CKD. In addition, in this substudy no patient had a renal hemorrhage after
commencing on an mTOR inhibitor. Our findings confirmed that renal angiomyolipomas
in subjects with TSC1 mutations develop on average at the later age, are relatively
smaller in size and less likely to be growing; however, by age 40 years, no difference
was observed in the percentage of patients with TSC1 and TSC2 mutations needing
intervention. The peak of appearance of new renal angiomyolipomas was observed in
patients aged between 18 and 40 years, but, given that angiomyolipomas can occur
later, lifelong surveillance is necessary. We found that pre-emptive intervention was
dramatically successful in altering the outcome compared to historical controls; with
high pre-emptive intervention rates but low rates of bleeding and other complications.
This validates the policy of surveillance and pre-emptive intervention recommended by
clinical guidelines.
Keywords: mTOR, registry, renal angiomyolipoma, TOSCA, tuberous sclerosis complex
INTRODUCTION
Tuberous sclerosis complex (TSC) is a rare, autosomal dominant
genetic disorder characterized by hamartomatous lesions in
multiple organs such as brain, kidneys, skin, lungs, eyes, and
heart (1, 2). Renal manifestations are one of the most common
causes of morbidity and were historically reported as the
primary cause of death in adult TSC patients (3–5). The relative
importance of mechanisms postulated to lead to impaired renal
function are unknown (6) but a major risk factor may be
intervention for renal angiomyolipomas (7).
Renal angiomyolipomas are the most common renal
manifestations in patients with TSC, with an estimated
prevalence ranging from 55 to 80% (8–11). They are usually
multiple and bilateral, progress with age and cause more
problems in females (12, 13). Angiomyolipomas >3 cm in
diameter have an increased risk of bleeding or invade adjacent
normal renal parenchyma, potentially leading to kidney
failure (10, 14). A retrospective cohort study showed that
modifiable factors such as hypertension, proteinuria, and
hyperfiltration occur frequently and early in patients with
TSC and could play an important role in the development
of chronic kidney disease (CKD) in these patients (15).
Renal cysts, although asymptomatic in most patients, may be
aggressive due to associated polycystic disease in a minority
of patients and can even result in development of end stage
renal disease in childhood or early adulthood (10, 16). Mutation
studies have shown the occurrence and severity of TSC-
associated renal angiomyolipomas and cysts to be higher
among patients with TSC2 mutation than those with TSC1
mutation (8, 17).
Previously we have reported interim analysis data of
the TOSCA (TuberOus SClerosis registry to increase
disease Awareness) study, highlighting the burden of TSC-
associated renal angiomyolipoma and showed that renal
angiomyolipomas are initially asymptomatic, influenced by
gender and genotype and can occur in younger patients
(13). Here we present the final analysis data of the TOSCA
registry with detailed overall characteristics of TSC-
associated renal angiomyolipoma and its association with
age, gender, and genotype. We have also analyzed possible
risk factors for bleeding from renal angiomyolipomas
and for CKD in patients with TSC from the TOSCA renal
angiomyolipoma substudy.
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MATERIALS AND METHODS
The study methodology has been published previously (18).
In brief, TOSCA was a large-scale non-interventional study
in patients with TSC. The study was designed with a core
section and six ancillary substudies (research projects with more
detailed focus on subependymal giant cell astrocytomas, renal
angiomyolipoma, and lymphangioleiomyomatosis, genetics,
TSC-associated neuropsychiatric disorder, epilepsy, and patient’s
quality of life). Here we present findings from the core study and
renal angiomyolipoma substudy.
The TOSCA study was designed and conducted according to
the Guidelines for Good Clinical Practice and ethical principles
outlined in the Declaration of Helsinki. Written informed
consent was obtained from all patients, parents, or guardians
prior to enrolment with prior endorsement by the local human
research ethics committee.
TABLE 1 | Baseline patient demographics and clinical characteristics.
Characteristic All patients
(N = 2,211)
Patients with renal
angiomyolipoma
(N = 1062)
Patients by age at consent
≤2 years 282 (12.8) 25 (2.4)
>2 to ≤5 years 301 (13.6) 76 (7.2)
>5 to ≤9 years 334 (15.1) 133 (12.5)
>9 to ≤14 years 307 (13.9) 164 (15.4)
>14 to <18 years 138 (6.2) 79 (7.4)
≥18 to≤40 years 625 (28.3) 411 (38.7)
>40 years 224 (10.1) 174 (16.4)
Median (range) age at diagnosis of TSC,a
years
1.0 (<1–69) 1.0 (<1–67)
Gender
Male 1,059 (47.9) 447 (42.1)
Female 1,152 (52.1) 615 (57.9)
Genetic molecular testing performed 1,011 (45.7) 525 (49.4)
Genetic testing resultsb,c
No mutation identified 148 (14.6) 80 (15.2)
TSC1 mutation 191 (18.9) 63 (12.0)
TSC2 mutation 649 (64.2) 373 (71.0)
Both TSC1 and TSC2 mutations 5 (0.5) 2 (0.4)
Mutation variation typec
Only pathogenic mutation 663 (65.6) 343 (65.3)
Only variant of unknown significance 43 (4.3) 23 (4.4)
Both 23 (2.3) 5 (1.0)
Time from TSC clinical diagnosis to
molecular testing, months, mean (SD)
81.8 (116.58) 118.3 (133.4)
Patients with prenatal TSC diagnosis 154 (7.0) 53 (5.0)
SD, standard deviation; TSC, tuberous sclerosis complex.
Values are expressed as n (%) unless otherwise specified. aData available for 2,174
patients (all patients) and 1050 patients (cohort with renal angiomyolipoma at baseline).
bGenetic testing results were not available for 18 patients (all patients) and 7 patients
(cohort with renal angiomyolipoma at baseline). cPercentages were calculated from
number of patients with genetic molecular testing performed.
Participants and Procedure
In the core study, patients of any age with TSC were
enrolled from 170 sites across 31 countries and were
followed for up to 5 years. Investigators from 18 sites
across eight countries also agreed to participate in this
renal angiomyolipoma substudy and enrolled a total of 76
patients, after receiving separate informed consent from
the patients.
In the core study, patient data including demographics and
clinical features of TSC across all organ systems, comorbidities,
and rare manifestations, were collected at baseline and at regular
visits scheduled at a maximum interval of 1 year. For the
purpose of this manuscript, we presented data specific to renal
TABLE 2 | Clinical characteristics of renal angiomyolipoma in overall population.
Characteristic Baseline
N = 2,211
Follow-up 1
N = 2,099
Follow-up 2
N = 1,935
Follow-up 3
N = 1,664
Past history of renal
angiomyolipoma
1,062 (48.0) – – –
Median (range) age at
angiomyolipoma
diagnosis, years
13 (<1–67) – – –
Renal angiomyolipoma
ongoing during the
studya
1,024 (96.4) 1,024 (96.0) 1,002 (96.3) 909 (96.2)
Multiple 901 (88.0) 896 (87.5) 880 (87.8) 822 (90.4)
Bilateral 859 (83.9) 854 (83.4) 834 (83.2) 784 (86.2)
Lesion >3 cm 342 (33.4) 327 (31.9) 320 (31.9) 282 (31.0)
Growing 216 (21.1) 193 (18.8) 205 (20.5) 168 (18.5)
Renal angiomyolipoma
symptoms and
complicationsb
None 840 (82.0) 894 (87.3) 885 (88.3) 816 (89.8)
Elevated blood
pressure
58 (5.7) 48 (4.7) 42 (4.2) 38 (4.2)
Hematuria (blood in
urine)
43 (4.2) 31 (3.0) 22 (2.2) 20 (2.2)
Hemorrhage 55 (5.4) 16 (1.6) 15 (1.5) 13 (1.4)
Impaired renal
function
39 (3.8) 35 (3.4) 36 (3.6) 34 (3.7)
Pain 63 (6.2) 37 (3.6) 27 (2.7) 17 (1.9)
Other 30 (2.9) 13 (1.3) 16 (1.6) 12 (1.3)
Patients received
treatment for
angiomyolipomac
315 (29.7) 300 (28.1) 321 (30.8) 288 (30.5)
mTOR inhibitor 144 (45.7) 49 (16.3) 28 (8.7) 26 (9.0)
Embolization 141 (44.8) 9 (3.0) 9 (2.8) 3 (1.0)
Nephrectomy 63 (20.0) 5 (1.7) 3 (0.9) 1 (0.3)
Resection 21 (6.7) 1 (0.3) 2 (0.6) 0
Dialysis 4 (1.3) 1 (0.3) 1 (0.3) 0
Other 13 (4.1) 1 (0.3) 5 (1.6) 1 (0.3)
mTOR, mammalian target of rapamycin.
Values are expressed as n (%) unless otherwise specified. aPercentages calculated based
on denominator of patients with history of renal angiomyolipoma. bPercentages calculated
from number of patients with renal angiomyolipoma ongoing during the study. bThe
numbers include patients who experienced more than one symptoms simultaneously.
cTreatment received as monotherapy or polytherapy.
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angiomyolipoma including occurrence rate, annual incidence
of newly diagnosed angiomyolipoma, maximum diameter on
ultrasound or magnetic resonance imaging, clinical symptoms
and complications, and management at baseline and during
follow-up. The number of patients who completed follow-up 4
and follow-up 5 visits were low due to their late enrolment in the
study, and hence follow-up data of only the first 3 years of the
core study are reported here.
In the 76 patients in the renal substudy data was collected on;
prevalence and size of renal angiomyolipomas and complication
rates (including bleeding, hypertension, and CKD). We also
present the effects of treatment with embolization or mammalian
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FIGURE 1 | Patients with history of renal angiomyolipoma and intervention received across age groups at baseline.
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FIGURE 2 | Newly diagnosed renal angiomyolipoma after baseline visit.
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target of rapamycin (mTOR) inhibitors on the risk of renal
impairment. For the substudy, only the baseline data are reported
here, as very few patients had follow-up visits due to their late
enrolment in the study.
Data Analyses
All eligible patients enrolled in the TOSCA registry and
renal angiomyolipoma substudy, without any major protocol
deviations, were included in the analysis. Given that the
study was observational in nature, results reported in this
manuscript are primarily descriptive statistics. Continuous
variables were evaluated quantitatively (e.g., frequency, mean,
standard deviation, median, range), and categorical variables
(e.g., presence/absence of amanifestation) were analysed in terms
of frequency distribution at baseline and at follow-ups.
The Cochran–Mantel–Haenszel test was performed to
evaluate the rates of renal angiomyolipomas stratified by
age groups (<18 and ≥18 years), gender (male and female)
and mutation (TSC1 and TSC2). The exact binomial test
was used to evaluate the difference between proportion of
patients with renal angiomyolipomas and those received
treatment among both genders, regardless of age, and genetic
mutation. Furthermore, we evaluated reported association
of angiomyolipoma-related variables at baseline visit (rates
of angiomyolipomas, angiomyolipomas with lesion >3 cm,
growing angiomyolipomas, treatment of angiomyolipomas and
symptoms) by age (<18 vs. ≥18 years), gender (male vs. female)
and mutation (TSC1 vs. TSC2) using Chi-square test. Statistical
significance was set at p < 0.05.
RESULTS
Findings From the Core Study
A total of 2,214 patients were enrolled from 170 sites across
31 countries. Of these, data of 2,211 eligible patients were
analysed. Data of three patients were excluded due to major
protocol deviations. Most patients were enrolled at sites where
the principal investigators were pediatric neurologists (53%) or
neurologists (17%).
Baseline demographics and clinical characteristics are
summarized in Table 1. There were more females (52.1%) than
males (47.9%), the majority of patients were under the age of
18 years (61.6%) and the median age at consent for the study
was 13 years. The median age at first TSC diagnosis was 1
year (mean 6.9 years, range: <1–69 years). Molecular genetic
testing was performed in 1,011 patients (45.7%). Of these, 64.2%
had a TSC2 mutation and 18.9% TSC1 mutation. In 14.6% of
patients, no mutation was identified. Of the 1,011 tested patients,
663 (65.6%) had pathogenic mutation, 43 (4.3%) had a variant
of unknown significance and 23 patients (2.3%) had both a
pathogenic mutation and variant of unknown significance.
In 282 patients, the pathogenicity of the mutation was not
recorded. Prenatal diagnosis of TSC was reported in 154 patients
(7%). Parents of 1,036 of 2,211 patients (56.3%) were evaluated
for TSC. Of these, 180 (17.4%) had mother, 126 (12.2) had
fathers and 4 (0.4%) had both parents diagnosed with TSC.
A considerable proportion of patients (23.6%) had relatives
affected with TSC and patients with relatives also enrolled in
TOSCA (10.6%).
Clinical Characteristics of Renal
Angiomyolipomas
A history of renal angiomyolipomas was reported in 1,062
(48%) patients (Table 2, Figure 1). Baseline demographics of
cohort with renal angiomyolipomas were similar to the overall
cohort (Table 1). Of 1,024 patients (96.4%) with ongoing renal
angiomyolipoma, 901 (88%) had multiple lesions, 859 (83.9%)
had bilateral lesions, 342 (33.4%) had lesions >3 cm in size and
216 (21.1%) had growing lesions. The median age at diagnosis
Within 5 years 5 to 10 years 10 to 15 years >15 years
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FIGURE 3 | Time since interventions prior to baseline. mTOR, mammalian target or rapamycin.
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was 13 years (mean 17 years, range <1–67 years). Median
time from the previous scan to last assessment was 1 year
(range, <1–21).
Renal angiomyolipomas were asymptomatic in most patients
(840 of 1,024 patients, 82%). Very few patients experienced renal
angiomyolipoma-related symptoms or complications (Table 2).
After baseline visit, newly diagnosed renal angiomyolipomas
were reported in 22 (2.1%), 21 (2.0%), and 21 (2.2%) patients at
follow-up 1, follow-up 2, and follow-up 3, respectively (Figure 2).
A total of 315 patients (29.7%) had received treatment for renal
angiomyolipomas at baseline. In these patients, mTOR inhibitors
(45.7%), embolization (44.8%), and nephrectomies (20%) were
the common treatment modalities. During the follow-ups,
more patients received treatment with mTOR inhibitors than
embolization (Table 2), and mTOR inhibitors appear to become
a predominant treatment in recent years (Figure 3). However,
the rate of nephrectomy was similar in each period prior
to baseline.
Relationship of Renal Angiomyolipoma
With Age
The proportion of patients with angiomyolipomas increased with
age (from 8.9% in patients aged≤2 years to 77.7% in patients aged
>40 years. Similarly, use of pre-emptive treatment increased with
age (Figure 1). Newly diagnosed renal angiomyolipomas were
more common in adults (Figure 2). There was an increased rate
of symptoms and complications with age (Table 3). Embolization
TABLE 3 | Renal angiomyolipoma symptoms and complications stratified by age.
Complication and
symptom
Overall
(N = 2,211)
Age at consent, years
≤2
(n = 282)
>2 to ≤5
(n = 301)
>5 to ≤9
(n = 334)
>9 to ≤14
(n = 307)
>14 to <18
(n = 138)
≥18 to ≤40
(n = 625)
>40
(n = 224)
None 840 (82.0) 23 (100.0) 74 (100.0) 122 (96.1) 147 (93.0) 71 (92.2) 298 (74.7) 105 (63.3)
Elevated blood pressurea 58 (5.7) 0 (0) 0 (0) 0 (0) 5 (3.2) 5 (6.5) 25 (6.3) 23 (13.9)
Hemorrhagea 43 (4.2) 0 (0) 0 (0) 0 (0) 2 (1.3) 1 (1.3) 23 (5.8) 17 (10.2)
Haematuriaa 55 (5.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 37 (9.3) 18 (10.8)
Impaired renal functiona 39 (3.8) 0 (0) 0 (0) 1 (0.8) 2 (1.3) 0 (0) 16 (4.0) 20 (12.0)
Paina 63 (6.2) 0 (0) 0 (0) 1 (0.8) 1 (0.6) 1 (1.3) 38 (9.5) 22 (13.3)
Other 30 (2.9) 0 (0) 0 (0) 3 (2.4) 2 (1.3) 1 (1.3) 17 (4.3) 7 (4.2)
All the values are expressed as n (%). aThe numbers include patients who experienced more than one symptom simultaneously.
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FIGURE 4 | Treatment modalities for renal angiomyolipomas by age groups. mTOR, mammalian target or rapamycin.
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TABLE 4 | Clinical characteristics of renal angiomyolipoma by gender.
Characteristics Female
N = 1,152
Male
N = 1,059
Odds ratio
(95% CI)
P-value
Past history of renal
angiomyolipoma
615 (53.4) 447 (42.2) 1.6 (1.3, 1.9) <0.0001
Median (range) age at
angiomyolipoma diagnosis,
years
14 (<1–63) 11 (<1–67) – 0.9891
Renal angiomyolipoma
ongoing during the studya
590 (95.9) 434 (97.1)
Multiple 524 (88.8) 377 (86.9) 1.2 (0.8, 1.8) 0.3436
Bilateral 502 (85.1) 357 (82.3) 1.3 (0.9, 1.8) 0.1585
Lesion >3 cm 212 (35.9) 130 (30.0) 1.4 (1.1, 1.9) 0.0119
Growing 135 (22.9) 81 (18.7) 1.4 (1.0, 1.9) 0.0439
Renal angiomyolipoma signs
and symptomsb,c
None 466 (79.0) 374 (86.2) 0.6 (0.4, 0.8) 0.0031
Elevated blood pressure 31 (5.3) 27 (6.2) 0.8 (0.5, 1.4) 0.5083
Haematuria (blood in urine) 29 (4.9) 14 (3.2) 1.6 (0.8, 3.0) 0.1829
Hemorrhage 41 (6.9) 14 (3.2) 2.2 (1.2, 4.2) 0.0090
Impaired renal function 27 (4.6) 12 (2.8) 1.7 (0.8, 3.4) 0.1345
Pain 50 (8.5) 13 (3.0) 3.0 (1.6, 5.6) 0.0003
Others 22 (3.7) 8 (1.8) 2.1 (0.9, 4.7) 0.0771
Treatment received for renal
angiomyolipomad
203 (33.0) 112 (25.1)
mTOR inhibitor 95 (46.8) 49 (43.8) 1.1 (0.7, 1.78) 0.6395
Embolization 84 (41.4) 57 (50.9) 0.7 (0.4, 1.1) 0.0894
Nephrectomy 47 (23.2) 16 (14.3) 1.8 (1.0, 3.4) 0.0629
Resection 16 (7.9) 5 (4.5) 1.8 (0.6, 5.1) 0.2503
Dialysis 3 (1.5) 1 (0.9) 1.7 (0.2, 16.1) 0.6618
Other 10 (4.9) 3 (2.7) 1.9 (0.5, 6.9) 0.3428
CI, confidence interval; mTOR, mammalian target of rapamycin.
Values are expressed as n (%) unless otherwise specified. aPercentages calculated based
on denominator of patients with history of renal angiomyolipoma. bPercentages calculated
from number of patients with renal angiomyolipoma ongoing during the study. cThe
numbers include patients who experienced more than one symptom simultaneously.
dTreatment received as monotherapy or polytherapy.
was more common in adults (54% vs. 9.2%), whereas children
were mostly treated with mTOR inhibitors (73.8 vs. 38.4%),
Figure 4).
Relationship of Renal Angiomyolipoma
With Gender
Of the 2,211 enrolled patients, 1,152 (52.1%) were female and
1,059 (47.9%) were male. A history of renal angiomyolipomas
was reported at a significantly higher frequency in female than
male patients (53.4 vs. 42.2%, p < 0.0001, Table 4). Newly
diagnosed renal angiomyolipomas were also more common in
female patients (2.3 vs. 1.8%). The gender difference (female
vs. male) in the rates of renal angiomyolipomas remained
statistically significant when stratified by age [<18 years [38.97
vs. 31.54%]; p < 0.0001 and ≥18 years [71.35 vs. 65.18%]; p
< 0.0001].
The median age at diagnosis of renal angiomyolipomas in
female patients was 14 years (mean 18.4 years, range <1–63
years), while it was 11 years (mean 15.1 years, range <1–67
years) in male patients. The difference in the age at diagnosis
between male and female patients were not significant (p =
0.9891). Five hundred and ninety females and 434 males had
renal angiomyolipomas ongoing during the study. There was
no significant differences between females and males in the
occurrence of multiple lesions (88.8 vs. 86.9%, p = 0.3436)
and bilateral angiomyolipomas (85.1 vs. 82.3%, p = 0.1585).
Compared to males, females had significantly higher rates of
lesions >3 cm in size (35.9 vs. 30.0%, p = 0.0119) and growing
lesions (22.9 vs. 18.7%, p = 0.0439) at baseline. In both male
and female patients, renal angiomyolipomas were asymptomatic
in most patients at baseline (male: 86.2 vs. female: 79%).
Most angiomyolipoma-related symptoms occurred equally in
females and males. These include elevated blood pressure (5.3
vs. 6.2%, p = 0.5083), haematuria (4.9 vs. 3.2%, p = 0.1829) and
impaired renal function (4.6 vs. 2.8%, p = 0.1345). However,
compared to males, females had significantly higher rates of
hemorrhage (6.9 vs. 3.2%, p = 0.0090) and pain (8.5 vs. 3%,
p = 0.0003). Overall, the rate of intervention at baseline were
significantly higher among females than males (33 vs. 25.1%, p
= 0.0058). However, there was no significant gender difference
(male vs. female) observed in the rates of specific interventions:
embolization (50.9 vs. 41.4%; p= 0.0894), mTOR inhibitors (46.8
vs. 43.8%; p= 0.6395), nephrectomy (23.2 vs. 14.3%; p= 0.0629),
resection (7.9 vs. 4.5%; p = 0.2503), and dialysis (1.5 vs. 0.9%;
p= 0.6618).
Relationship of Renal Angiomyolipoma
With Mutation Type
The prevalence of angiomyolipomas was significantly higher in
patients with TSC2 vs. TSC1mutations (57.5 vs. 33%, p< 0.0001;
Table 5). The mean age at diagnosis of renal angiomyolipomas
was 13.3 years (median, 9 years, range <1–59 years) in patients
with a TSC2 mutations, while it was 22.5 years (median 21
years, range <1–60 years) in those with a TSC1 mutations.
Patients with TSC2 mutations also had significantly higher rates
of multiple angiomyolipomas (92.3 vs. 67.2, p< 0.0001), bilateral
angiomyolipomas (87 vs. 47.5%, p < 0.0001) angiomyolipoma
lesions >3 cm (31.2 vs. 11.5%, p = 0.0013) and growing
angiomyolipomas (23.2 vs. 9.8%, p= 0.0150).
Similar to the overall sample, renal angiomyolipomas
were asymptomatic in most patients with TSC1 (90.2%)
and TSC2 (83.1%) mutations. However, bleeding events
were observed only in patients with TSC2 mutations
(haematuria, 3.9% and hemorrhage, 5.2%). No significant
difference in the rates of intervention of any sort was observed
between those with TSC1 mutations and TSC2 mutations
(p < 0.0801, Table 5).
Other Renal Manifestations
The other renal features reported at baseline were multiple renal
cysts (24.6%), polycystic kidney disease (proven TSC2/PKD1
mutation; 3.4%), renal malignancy (1.4%), and impaired renal
function (non-angiomyolipoma-related; 1.9%) (Table 6).
Compared with patients with a TSC1 mutation, those
with TSC2 mutations had a higher occurrence of multiple
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TABLE 5 | Clinical characteristics of renal angiomyolipoma by mutational status.
Characteristics Patients with
TSC1mutation
N = 196
Patients
with TSC2
mutation
N = 654
Odds ratio
(95% CI)
p-value
Past history of renal
angiomyolipoma
63 (33.0) 373 (57.5) 2.8 (2.0, 3.9) <0.0001
Male 28 (44.4) 169 (45.3) – –
Female 35 (55.6) 204 (54.7) – –
Median (range) age at
angiomyolipoma diagnosis,
years
21 (<1–60) 9 (<1–59) – 0.0035
Renal angiomyolipoma
ongoing during the studya
61 (93.8) 362 (96.5)
Multiple 41 (67.2) 334 (92.3) 6.1 (3.1, 11.8) <0.0001
Bilateral 29 (47.5) 315 (87.0) 8.1 (4.4, 14.7) <0.0001
Lesion >3 cm 7 (11.5) 113 (31.2) 3.6 (1.6, 8.2) 0.0013
Growing 7 (11.5) 85 (23.5) 2.9 (1.2, 7.2) 0.0150
Renal angiomyolipoma
signs and symptomsb
None 55 (90.2) 301 (83.1) 0.6 (0.2, 1.3) 0.1881
Elevated blood pressure 4 (6.6) 23 (6.4) 0.9 (0.3, 2.8) 0.9098
Haematuria (blood in
urine)
0 14 (3.9) NE 0.1234
Hemorrhage 0 19 (5.2) NE 0.0709
Impaired renal function 1 (1.6) 10 (2.8) 1.7 (0.2, 13.2) 0.6297
Pain 2 (3.3) 24 (6.6) 2.0 (0.5, 8.8) 0.3335
Other 0 9 (2.5) NE 0.2195
Treatment received for
renal angiomyolipomaa,c
9 (13.8) 103 (27.5) – p<0.0801
mTOR inhibitor 4 (44.4) 56 (54.4) 1.5 (0.4, 5.9) 0.5670
Embolization 2 (22.2) 41 (39.8) 2.3 (0.5, 11.7) 0.2983
Nephrectomy 3 (33.3) 23 (22.3) 0.6 (0.1, 2.5) 0.4534
Resection 1 (11.1) 6 (5.8) 0.5 (0.1, 4.6) 0.5299
Dialysis 0 1 (1.0) NE (NE) 0.7665
Other 0 3 (2.9) NE (NE) 0.6038
CI, confidence interval; mTOR, mammalian target of rapamycin; TSC, tuberous
sclerosis complex.
Values are expressed as n (%) unless otherwise specified. aPercentages calculated based
on denominator of patients with history of renal angiomyolipoma. bPercentages calculated
from number of patients with renal angiomyolipoma ongoing during the study. cTreatment
received as monotherapy or polytherapy.
renal cysts (33.6 vs. 13.3%) and polycystic kidney disease
(4.7 vs. 0%).
Findings From the Angiomyolipoma
Substudy
A total of 76 patients [24 (31.6%) male and 52 (68.4%) female]
were enrolled into the substudy from eight countries [France (n
= 25), United Kingdom (n= 15), Belgium and Japan (n = 11,
each), Turkey (n = 6), Poland (n = 4), and Germany and Spain
(n= 2, each)]. Most patients were Caucasians (57 patients, 75%).
Hypertension was reported in 19 patients (25%). Pre-existing
antihypertensive medication was reported in 12 patients (63.2%).
TABLE 6 | Rates of other renal manifestations at baseline in overall population
and by mutational status.
Overall
N = 2,211
Patients with
TSC1 mutation
N = 196
Patients with
TSC2 mutation
N = 654
Renal manifestations in
patients with
angiomyolipomas
Multiple renal cysts 544 (24.6) 26 (13.3) 220 (33.6)
Polycystic kidneys Not
applicable*
0 31 (4.7)
Renal malignancy 31 (1.4) 4 (2.0) 8 (1.2)
Renal manifestations in
patients without
angiomyolipoma
Impaired renal function 43 (1.9) 6 (3.1) 18 (2.8)
CI, confidence interval; mTOR, mammalian target of rapamycin; N/A, not applicable; TSC,
tuberous sclerosis complex.
Values are expressed as n (%). *PKD was observed only in those with TSC2 mutations.
Risk Factors of Bleeding From Renal
Angiomyolipomas
Of the 76 patients with renal angiomyolipomas, hemorrhage
was reported in three patients at baseline, who were not taking
mTOR inhibitors (patients aged 31, 34, and 43 years). All three
of them were female and had TSC2 mutations, with largest
angiomyolipoma diameter between 66 and 96 mm.
Risk Factors of Chronic Kidney Disease
A total of 42 patients reported CKD at baseline. Of these,
seven (16.7%) had grade 3a/3b CKD (GFR 30–59), and four
(9.5%) had grade 4 CKD (GFR 15–29). Thirty-six of 42
CKD patients had typical renal angiomyolipomas, eight had
atypical renal angiomyolipomas and two had other renal
angiomyolipomas. There was no correlation between CKD stage
and type of angiomyolipoma. Mean age at diagnosis of renal
angiomyolipoma was 14.5 years for patients with grade 1 CKD,
26.4 years for patients with grade 2 CKD, 35 years for patients
with grade 3a CKD, 22 years for patients with grade 3b CKD
and 34 years for patients with grade 4 CKD. Size of renal
angiomyolipomas were between 3 and 180mm. Simple cysts were
reported in 16 patients (38.1%) and polycystic kidney disease in
two patients (4.8%). Of the three patients with CKD and cysts,
but without renal angiomyolipoma at baseline, two had grade 1
CKD and one had grade 2 CKD.
Effect of Embolization or mTOR Inhibitor
Treatment on CKD and Bleeding
Out of 76 patients enrolled, 47 patients received treatment; 20
were treated with mTOR inhibitors alone, four with embolization
alone and five with both mTOR inhibitors and embolization
at baseline. Among the 20 patients who were treated with
mTOR inhibitors alone, eight (40%) had grade 2 CKD, four
(20%) had grade 3a/3b CKD, and two had grade 4 CKD. No
patient had unselected proteinuria while 7 patients (35%) had
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albuminuria grade 1. No patient on mTOR inhibitors alone had
renal hemorrhage.
Among the four patients treated with embolization alone, one
(25%) had grade 1 CKD, one (25%) had grade 2 CKD, and one
(25%) had grade 4 CKD. Data was missing for one patient. One
(25%) patient had proteinuria, while two (50%) had grade 1
albuminuria. No patient had renal hemorrhage.
DISCUSSION
The results from this final analysis have several novel
observations. The prevalence of angiomyolipoma as well as
rates of angiomyolipoma-related complications were higher in
females than in male patients. This effect might be attributed
to the presence of estrogen and progesterone receptors on the
tumors (19). However, the mechanism of hormonal modulation
on angiomyolipoma growth is not yet known. Female patients
were alsomore likely to have bilateral, multiple and growing renal
angiomyolipoma than male patients. This was in line with the
other studies suggesting a higher propensity of angiomyolipoma
growth in female patients (9, 20). Angiomyolipomas were
dignosed at a later age in females (median age 14 years) than in
male patients (median age 11 years), but this difference was not
statistcally significant.
In our previous publication from the TOSCA core section
interim analysis (13), we reported that the occurrence rate
of renal angiomyolipomas was lower in the TOSCA cohort
compared to other published literature (8, 9). Rates of haematuria
and hypertension were also lower compared with those reported
in TSC patients in other studies (6, 7, 21, 22), this may
be a reflection of the age relatively young age of our
subjects and possibly under-ascertainment. These lower rates
of occurrence of renal angiomyolipomas and angiomyolipoma-
related complications could be explained by a different (younger)
age range of our population; however the current analysis shows
that angiomyolipoma prevalence rose progressively with age, to
77.7% in those over 40 years of age, whereas complication rates
remained much lower than in other studies. This suggests that
active surveillance and a policy of pre-emptive treatment may
have been successful in altering the natural history of renal TSC.
Patients with TSC2 mutations were reported to exhibit a
higher incidence and severity of both renal angiomyolipoma
and cysts than those with TSC1 mutations (8). In our study,
the prevalence of angiomyolipoma was significantly higher in
those with TSC2 mutations. This was in line with the previous
other reports (7, 8, 17, 23). We also observed that patients
with TSC2 mutations had angiomyolipoma at early age and
experienced higher rates of bleeding complications (haematuria
and hemorrhage). Rates of multiple angiomyolipomas, bilateral
angiomyolipoma, renal angiomyolipoma lesions of >3 cm were
significantly higher in those with TSC2 mutations than those
with TSC1 mutations. Furthermore, more patients with TSC2
mutations received intervention for renal angiomyolipoma than
those with TSC1mutations.
As expected polycystic kidney disease was only found in
those with TSC2 mutations because it is the result of a deletion
stretching across the TSC2 and PKD1 genes on chromosme 16
(The “contiguous gene syndrome”) (24).
The study showed that pre-emptive treatment was used
increasingly commonly with age (Figure 1) and this was
associated with a very low rate of bleeding and significant renal
impairment. Figures 3, 4 show that mTOR inhibitors are now the
most commonly used treatment.
Despite the fact that overall prevalence of hemorrhage and
CKD was too low to accurately define risk factors, in our sub-
study we observed that all the three patients who had hemorrhage
had TSC2 mutation. Majority of the patients had grade 1/2
CKD (31 patients, 73.8%). Patients with CKD grade 2 or more
were older but there was a clear trend for more advanced
CKD stages.
Renal malignancy has been reported in about 2–4% of
patients with TSC (25), which is much higher than that
reported in a comparable age group in the general population
(26). The occurrence rate of renal malignancy observed in
this cohort was lower (1.4%) than that reported previously,
in TSC (8, 25).
CONCLUSION
Renal angiomyolipomas are the major kidney risk for those with
TSC; other renal complications are less common.We have shown
a marked increase in the prevalence of intervention for renal
angiomyolipomas, from <10% in those under 2 years of age to
48% in those over 40. The risk of needing an intervention was
higher and begins earlier in those with a TSC2 mutation, but the
difference disappears by age 40 years. Gender differences were
much smaller, but in females the occurrence of angiomyolipomas
was significantly greater, as were angiomyolipomas >3 cm and
the need for intervention. However, there was no absolute cut-
off between the differences in any of these categories which
means lifelong surveillance is important in all patients. In the
substudy of 76 subjects none had a renal hemorrhage after
commencing on an mTOR inhibitor. The most encouraging
finding was that pre-emptive intervention was dramatically
successful in altering the outcome compared to historical
controls; with high pre-emptive intervention rates but low rates
of bleeding and other complications. This validates the policy
of surveillance and pre-emptive intervention recommended by
clinical guidelines.
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biedribas Kliniskās izpētes Etikas komiteja, Ethics Committee
for Clinical Research; The First Affiliated Hospital of the
Fourth Military Medical University; Zhongshan Hospital
Fudan University.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by all ethics committees involved in the TOSCA
study (see list of ethics committees in article). Written informed
consent to participate in this study was provided by the
participants’ legal guardian/next of kin.
AUTHOR CONTRIBUTIONS
JK, EB, MB, PC, MD, JF, MF, CH, SJ, JL, AM, RN, VS, RT,
BZ, AJ, and MS designed the study, patient accrual, clinical
care, data interpretation, drafted, revised, final review, and
approval of the manuscript. TC, VC, GB, PV, CF, FO’C, JQ,
YT, and SY designed the study, data interpretation, drafted,
revised, final review, and approval of the manuscript. LD’A
designed the study, trial management, data collection, data
analysis, data interpretation, drafted, revised, final review,
and approval of the manuscript. RM designed the study,
data analysis, data interpretation, drafting, revised, final
review, and approval of the manuscript. SS designed the
study, trial statistician, data analysis, data interpretation,
drafted, revising, final review, and approval of the manuscript.
All authors contributed to the article and approved the
submitted version.
FUNDING
The study was funded by Novartis Pharma AG. Novartis
has contributed to study design, data analysis and the
decision to publish. Novartis authors reviewed the draft
for submission.
ACKNOWLEDGMENTS
We thank patients and their families, investigators, and staff
from all participating sites. The authors thank Manojkumar
Patel (Novartis Healthcare PVT Ltd.) for providing medical
writing support, which was funded by Novartis Pharmaceutical
Corporation in accordance with Good Publication Practice
(GPP3) guidelines (http://www.ismpp.org/gpp3).
TOSCA Investigators
Japan: Nobuo Shinohara, Shigeo Horie, Masaya Kubota,
Jun Tohyama, Katsumi Imai, Mari Kaneda, Hideo Kaneko,
Yasushi Uchida, Tomoko Kirino, Shoichi Endo, Yoshikazu
Inoue, Katsuhisa Uruno; Turkey: Ayse Serdaroglu, Zuhal
Yapici, Banu Anlar, Sakir Altunbasak; Russia: Olga Lvova, Oleg
Valeryevich Belyaev, Oleg Agranovich, Elena Vladislavovna
Levitina, Yulia Vladimirovna Maksimova, Antonina Karas;
China: Yuwu Jiang, Liping Zou, Kaifeng Xu, Yushi Zhang,
Guoming Luan, Yuqin Zhang, Yi Wang, Meiling Jin, Dingwei
Ye, Weiping Liao, Liemin Zhou, Jie Liu, Jianxiang Liao,
Bo Yan, Yanchun Deng, Li Jiang, Zhisheng Liu, Shaoping
Huang, Hua Li; Korea: Kijoong Kim; Taiwan: Pei-Lung
Chen, Hsiu-Fen Lee, Jeng-Dau Tsai, Ching-Shiang Chi,
Chao-Ching Huang; Australia: Kate Riney, Deborah Yates,
Patrick Kwan; Thailand: Surachai Likasitwattanakul, Charcrin
Nabangchang, Lunliya Thampratankul Krisnachai Chomtho,
Kamornwan Katanyuwong, Somjit Sriudomkajorn; South
Africa: Jo Wilmshurst; Israel: Reeval Segel, Tal Gilboa,
Michal Tzadok, Aviva Fattal- Valevski; Greece: Panagiotis
Papathanasopoulos, Antigone Syrigou Papavasiliou, Stylianos
Giannakodimos, Stylianos Gatzonis, Evangelos Pavlou, Meropi
Tzoufi; Netherlands: A.M.H. Vergeer; Belgium: Marc Dhooghe,
Hélène Verhelst, Filip Roelens, Marie Cecile Nassogne,
Pierre Defresne, Liesbeth De Waele, Patricia Leroy, Nathalie
Demonceau, Benjamin Legros, Patrick Van Bogaert, Berten
Ceulemans, Lina Dom; France: Pierre Castelnau, Anne De
Saint Martin, Audrey Riquet, Mathieu Milh, Claude Cances,
Jean-Michel Pedespan, Dorothee Ville, Agathe Roubertie,
Stéphane Auvin, Patrick Berquin, Christian Richelme, Catherine
Allaire, Sophie Gueden, Sylvie Nguyen The Tich, Bertrand
Godet; Spain: Maria Luz Ruiz Falco Rojas, Jaume Campistol
Planas, Antonio Martinez Bermejo, Patricia Smeyers Dura,
Susana Roldan Aparicio, Maria Jesus Martinez Gonzalez,
Javier Lopez Pison, Manuel Oscar Blanco Barca, Eduardo
Lopez Laso, Olga Alonso Luengo, Francisco Javier Aguirre
Rodriguez, Ignacio Malaga Dieguez, Ana Camacho Salas,
Itxaso Marti Carrera, Eduardo Martinez Salcedo, Maria
Eugenia Yoldi Petri, Ramon Cancho Candela; Portugal: Ines
da Conceicao Carrilho, Jose Pedro Vieira, José Paulo da
Silva Oliveira Monteiro, Miguel Jorge Santos de Oliveira
Ferreira Leao, Catarina Sofia Marceano Ribeiro Luis, Carla
Pires Mendonca; Lithuania: Milda Endziniene; Latvia: Jurgis
Strautmanis; Estonia: Inga Talvik; Italy: Maria Paola Canevini,
Antonio Gambardella, Dario Pruna, Salvatore Buono, Elena
Fontana, Bernardo Dalla Bernardina; Romania: Carmen
Burloiu, Iuliu Stefan Bacos Cosma, Mihaela Adela Vintan,
Laura Popescu; Czech Republic: Karel Zitterbart; Slovakia:
Jaroslava Payerova, Ladislav Bratsky, Zuzana Zilinska; Austria:
Ursula Gruber-Sedlmayr, Matthias Baumann, Edda Haberlandt,
Kevin Rostasy, Ekaterina Pataraia; United Kingdom: Frances
Elmslie, Clare Ann Johnston, Pamela Crawford; Denmark:
Peter Uldall; Sweden: Paul Uvebrant, Olof Rask; Norway: Marit
Bjoernvold, Eylert Brodtkorb, Andreas Sloerdahl, Ragnar Solhoff,
Martine Sofie Gilje Jaatun; Poland: Marek Mandera, Elzbieta
Janina Radzikowska, Mariusz Wysocki; Germany: Michael
Fischereder, Gerhard Kurlemann, Bernd Wilken, Adelheid
Wiemer-Kruel, Klemens Budde, Klaus Marquard, Markus Knuf,
Andreas Hahn, Hans Hartmann, Andreas Merkenschlager,
Regina Trollmann.
Frontiers in Neurology | www.frontiersin.org 11 September 2020 | Volume 11 | Article 972
Kingswood et al. Prevalence and Outcome of Renal Angiomyolipomas in TSC
REFERENCES
1. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. (2008)
372:657–68. doi: 10.1016/S0140-6736(08)61279-9
2. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl
J Med. (2006) 355:1345–56. doi: 10.1056/NEJMra055323
3. Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death
in patients with tuberous sclerosis. Mayo Clin Proc. (1991) 66:792–
6. doi: 10.1016/S0025-6196(12)61196-3
4. Amin S, Lux A, Calder N, Laugharne M, Osborne J, O’Callaghan F. Causes
of mortality in individuals with tuberous sclerosis complex. Dev Med Child
Neurol. (2017) 59:612–7. doi: 10.1111/dmcn.13352
5. Shepherd CW, Gomez MR. Mortality in the mayo clinic
tuberous sclerosis complex study. Ann N Y Acad Sci. (1991)
615:375–7. doi: 10.1111/j.1749-6632.1991.tb37786.x
6. Kingswood C, Bolton P, Crawford P, Harland C, Johnson SR, Sampson
JR, et al. The clinical profile of tuberous sclerosis complex (TSC)
in the United Kingdom, a retrospective cohort study in the Clinical
Practice Research Datalink (CPRD). Eur J Paediatr Neurol. (2016) 20:296–
308. doi: 10.1016/j.ejpn.2015.11.011
7. Seyam R, Al Khudair W, Kattan SA, Faihan Al Otaibi M, Skaff F, Al Taweel
MW. The impact of renal angiomyolipoma on estimated glomerular filtration
rate in patients with tuberous sclerosis complex. Ann Saudi Med. (2016)
36:356–63. doi: 10.5144/0256-4947.2016.356
8. Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA. Renal
manifestations of tuberous sclerosis complex: Incidence, prognosis predictive
factors. Kidney Int. (2006) 70:1777–82. doi: 10.1038/sj.ki.5001853
9. Webb DW, Kabala J, Osborne JP. A population study of renal
disease in patients with tuberous sclerosis. Br J Urol. (1994)
74:151–4. doi: 10.1111/j.1464-410X.1994.tb16577.x
10. O’Callaghan FJ, Noakes MJ, Martyn CN, Osborne JP. An epidemiological
study of renal pathology in tuberous sclerosis complex. BJU Int. (2004)
94:853–7. doi: 10.1111/j.1464-410X.2004.05046.x
11. Cook JA, Oliver K, Mueller RF, Sampson J. A cross sectional study of
renal involvement in tuberous sclerosis. J Med Genet. (1996) 33:480–
4. doi: 10.1136/jmg.33.6.480
12. Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease.
Nephron Exp Nephrol. (2011) 118:e15–20. doi: 10.1159/000320891
13. Kingswood JC, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, et al.
Renal angiomyolipoma in patients with tuberous sclerosis complex: findings
from the TuberOus SClerosis registry to increase disease awareness. Nephrol
Dial Transplant. (2019) 34:502–8. doi: 10.1093/ndt/gfy063
14. Budde K, Gaedeke J. Tuberous sclerosis complex-associated
angiomyolipomas: focus on mTOR inhibition. Am J Kidney Dis. (2012)
59:276–83. doi: 10.1053/j.ajkd.2011.10.013
15. Janssens P, van Hoeve K, de Waele L, de Rechter S, Claes KJ, van de
Perre E, et al. Renal progression factors in young patients with tuberous
sclerosis complex: a retrospective cohort study. Pediatric Nephrol. (2018)
33:1–9. doi: 10.1007/s00467-018-4003-6
16. Samuels JA. Treatment of renal angiomyolipoma and other hamartomas in
patients with tuberous sclerosis complex. Clin J Am Soc Nephrol. (2017)
12:1196–202. doi: 10.2215/CJN.08150816
17. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, et al.
Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates
increased severity of TSC2, compared with TSC1, disease in multiple organs.
Am J Hum Genet. (2001) 68:64–80. doi: 10.1086/316951
18. Kingswood JC, Bruzzi P, Curatolo P, de Vries PJ, Fladrowski C, Hertzberg C,
et al. TOSCA - first international registry to address knowledge gaps in the
natural history and management of tuberous sclerosis complex. Orphanet J
Rare Dis. (2014) 9:182. doi: 10.1186/s13023-014-0182-9
19. Henske EP, Ao X, Short MP, Greenberg R, Neumann HP, Kwiatkowski
DJ, Russo I. Frequent progesterone receptor immunoreactivity in tuberous
sclerosis-associated renal angiomyolipomas. Mod Pathol. (1998) 11:665–
8. doi: 10.1097/00005392-199908000-00131
20. Ewalt DH, Sheffield E, Sparagana SP, Delgado MR, Roach ES. Renal lesion
growth in children with tuberous sclerosis complex. J Urol. (1998) 160:141–
5. doi: 10.1016/S0022-5347(01)63072-6
21. Bissler J, Cappell K, Charles H, Song X, Liu Z, Prestifilippo J, Gregory
C, Hulbert J. Long-term clinical morbidity in patients with renal
angiomyolipoma associated with tuberous sclerosis complex. Urology. (2016)
95:80–7. doi: 10.1016/j.urology.2016.04.027
22. Eijkemans MJC, Van Der Wal W, Reijnders LJ, Roes KCB, Van Waalwijk
Van Doorn-Khosrovani SB, Pelletier C, et al. Long-term follow-up assessing
renal angiomyolipoma treatment patterns, morbidity, and mortality: an
observational study in tuberous sclerosis complex patients in the Netherlands.
Am J Kidney Dis. (2015) 66:638–45. doi: 10.1053/j.ajkd.2015.05.016
23. Bhatt JR, Richard PO, Kim NS, Finelli A, Manickavachagam K, Legere L,
et al. Natural history of renal angiomyolipoma (AML): most patients with
large AMLs>4 cm can be offered active surveillance as an initial management
strategy. Eur Urol. (2016) 70:85–90. doi: 10.1016/j.eururo.2016.01.048
24. Henske EP, Józwiak S, Kingswood JC, Sampson JR, Thiele
EA. Tuberous sclerosis complex. Nat Rev Dis Primers. (2016)
2:16035. doi: 10.1038/nrdp.2016.35
25. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell
carcinoma. J Urol. (2006) 176:2353–8. doi: 10.1016/j.juro.2006.07.130
26. Yang P, Cornejo KM, Sadow PM, Cheng L, Wang M, Xiao Y, et al. Renal
cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol. (2014)
38:895–909. doi: 10.1097/PAS.0000000000000237
Conflict of Interest: JK, EB, TC, VC, PC, GB, JF, PV, MF, CF, CH, SJ, RN, FO’C,
JQ, MS, RT, MD, JL, AM, SY, MB, BZ, and AJ received honoraria and support
for travel from Novartis. VC received personal fees for consulting, lecture fees
and travel from Actelion, Bayer, Biogen Idec, Boehringer Ingelheim, Gilead,
GSK, MSD, Novartis, Pfizer, Roche, and Sanofi; grants from Actelion, Boehringer
Ingelheim, GSK, Pfizer, and Roche; personal fees for developing educational
material from Boehringer Ingelheim, and Roche. PV has been on the study
steering group of the EXIST-1, 2, and 3 studies sponsored by Novartis and co-PI
on two investigator-initiated studies part-funded by Novartis. RN received grant
support, paid to her institution, from Eisai and lectures fees from Nutricia,
Eisai, Advienne, and GW Pharma. YT received personal fee from Novartis for
lecture and for copyright of referential figures from the journals and received
grant from Japanese government for intractable epilepsy research. SJ was partly
financed by the EC Seventh Framework Programme (FP7/2007-2013; EPISTOP,
grant agreement No. 602391), the Polish Ministerial funds for science (years
2013–2018) for implementation of international co-financed project and the grant
EPIMARKER of the Polish National Center for Research and Development No.
STRATEGMED3/306306/4/2016. JK, PC, CH, JL, and JQ received research grant
from Novartis. RM and SS are employees of Novartis, while LD’A was a Novartis
employee at the time of manuscript concept approval.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Kingswood, Belousova, Benedik, Carter, Cottin, Curatolo, Dahlin,
D’Amato, Beaure d’Augères, de Vries, Ferreira, Feucht, Fladrowski, Hertzberg,
Jozwiak, Lawson, Macaya, Marques, Nabbout, O’Callaghan, Qin, Sander, Shah,
Takahashi, Touraine, Youroukos, Zonnenberg, Jansen and Sauter. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Neurology | www.frontiersin.org 12 September 2020 | Volume 11 | Article 972
